Factors Predicting Surgical Effort Using Explainable Artificial Intelligence in Advanced Stage Epithelial Ovarian Cancer.
Explainable Artificial Intelligence
complete cytoreduction
epithelial ovarian cancer
human factors
surgical complexity score
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Jul 2022
15 Jul 2022
Historique:
received:
19
05
2022
revised:
04
07
2022
accepted:
05
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
(1) Background: Surgical cytoreduction for epithelial ovarian cancer (EOC) is a complex procedure. Encompassed within the performance skills to achieve surgical precision, intra-operative surgical decision-making remains a core feature. The use of eXplainable Artificial Intelligence (XAI) could potentially interpret the influence of human factors on the surgical effort for the cytoreductive outcome in question; (2) Methods: The retrospective cohort study evaluated 560 consecutive EOC patients who underwent cytoreductive surgery between January 2014 and December 2019 in a single public institution. The eXtreme Gradient Boosting (XGBoost) and Deep Neural Network (DNN) algorithms were employed to develop the predictive model, including patient- and operation-specific features, and novel features reflecting human factors in surgical heuristics. The precision, recall, F1 score, and area under curve (AUC) were compared between both training algorithms. The SHapley Additive exPlanations (SHAP) framework was used to provide global and local explainability for the predictive model; (3) Results: A surgical complexity score (SCS) cut-off value of five was calculated using a Receiver Operator Characteristic (ROC) curve, above which the probability of incomplete cytoreduction was more likely (area under the curve [AUC] = 0.644; 95% confidence interval [CI] = 0.598−0.69; sensitivity and specificity 34.1%, 86.5%, respectively; p = 0.000). The XGBoost outperformed the DNN assessment for the prediction of the above threshold surgical effort outcome (AUC = 0.77; 95% [CI] 0.69−0.85; p < 0.05 vs. AUC 0.739; 95% [CI] 0.655−0.823; p < 0.95). We identified “turning points” that demonstrated a clear preference towards above the given cut-off level of surgical effort; in consultant surgeons with <12 years of experience, age <53 years old, who, when attempting primary cytoreductive surgery, recorded the presence of ascites, an Intraoperative Mapping of Ovarian Cancer score >4, and a Peritoneal Carcinomatosis Index >7, in a surgical environment with the optimization of infrastructural support. (4) Conclusions: Using XAI, we explain how intra-operative decisions may consider human factors during EOC cytoreduction alongside factual knowledge, to maximize the magnitude of the selected trade-off in effort. XAI techniques are critical for a better understanding of Artificial Intelligence frameworks, and to enhance their incorporation in medical applications.
Identifiants
pubmed: 35884506
pii: cancers14143447
doi: 10.3390/cancers14143447
pmc: PMC9316555
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet. 2015 Jul 18;386(9990):249-57
pubmed: 26002111
Gynecol Oncol. 2006 Jan;100(1):33-7
pubmed: 16153692
Clin Obstet Gynecol. 2020 Mar;63(1):74-79
pubmed: 31725415
Eur J Radiol. 2021 Feb;135:109471
pubmed: 33338759
Postgrad Med J. 2014 Mar;90(1061):149-54
pubmed: 24398594
Ann Surg Oncol. 2021 Jan;28(1):244-251
pubmed: 32472412
J Clin Med. 2021 Dec 24;11(1):
pubmed: 35011828
Gynecol Oncol. 2014 Jun;133(3):401-4
pubmed: 24878391
Int J Med Inform. 2020 Sep;141:104195
pubmed: 32485554
Cancer Control. 2021 Jan-Dec;28:10732748211044678
pubmed: 34693730
Cancers (Basel). 2021 Jul 09;13(14):
pubmed: 34298668
Clin Cancer Res. 2019 May 15;25(10):3006-3015
pubmed: 30979733
J Pers Med. 2022 Apr 10;12(4):
pubmed: 35455723
Zentralbl Gynakol. 2003 Mar-Apr;125(3-4):129-35
pubmed: 12961105
Br Dent J. 2016 Dec 16;221(12):752-754
pubmed: 27981996
Ann Surg. 2006 Sep;244(3):353-62
pubmed: 16926561
Int J Gynecol Cancer. 2015 Mar;25(3):512-20
pubmed: 25628106
Nat Biomed Eng. 2017 Sep;1(9):691-696
pubmed: 31015666
JAMA Surg. 2020 Feb 1;155(2):148-158
pubmed: 31825465
Gynecol Oncol. 2009 Jul;114(1):26-31
pubmed: 19395008
Obstet Gynecol. 1983 Apr;61(4):413-20
pubmed: 6828269
Ann Surg Oncol. 2019 Sep;26(9):2943-2951
pubmed: 31243666
Eur J Obstet Gynecol Reprod Biol. 2017 Jun;213:123-139
pubmed: 28457647
Int J Gynecol Cancer. 2020 Apr;30(4):436-440
pubmed: 32086362
J Clin Oncol. 2007 Aug 20;25(24):3621-7
pubmed: 17704411
Am J Obstet Gynecol. 2007 Dec;197(6):676.e1-7
pubmed: 18060979
J Med Ethics. 2020 Mar;46(3):205-211
pubmed: 31748206
Surgery. 2018 Nov;164(5):1117-1123
pubmed: 30149939
Int J Gynecol Cancer. 2016 Sep;26(7):1354-63
pubmed: 27648648
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
BMC Med Inform Decis Mak. 2020 Nov 30;20(1):310
pubmed: 33256715
JAMA. 2017 Jan 24;317(4):357-358
pubmed: 28118462
Int J Gynecol Cancer. 2019 May;29(4):651-668
pubmed: 30877144
Sci Robot. 2019 Dec 18;4(37):
pubmed: 33137719
Int J Gynecol Cancer. 2017 Sep;27(7):1534-1542
pubmed: 30814245
Big Data. 2021 Oct;9(5):331-342
pubmed: 34030465
Entropy (Basel). 2020 Dec 25;23(1):
pubmed: 33375658
Int J Gynecol Cancer. 2019 Oct;29(8):1327-1331
pubmed: 31420412
ANZ J Surg. 2008 Dec;78(12):1106-8
pubmed: 19087052
Cochrane Database Syst Rev. 2011 Feb 16;(2):CD007635
pubmed: 21328298
Gynecol Oncol. 2018 Aug;150(2):370-377
pubmed: 29929923
J Clin Oncol. 2005 Dec 1;23(34):8802-11
pubmed: 16314640
Clin Orthop Relat Res. 2009 Feb;467(2):402-11
pubmed: 18975041
Int J Comput Assist Radiol Surg. 2014 May;9(3):495-511
pubmed: 24014322
Arch Surg. 2002 May;137(5):611-7; discussion 617-8
pubmed: 11982478
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
J Ovarian Res. 2020 Sep 29;13(1):117
pubmed: 32993745
Gynecol Oncol. 2006 Dec;103(3):1070-6
pubmed: 16875720
Gynecol Oncol. 2013 Nov;131(2):347-51
pubmed: 23954901
CMAJ. 2020 Apr 14;192(15):E385-E392
pubmed: 32392499
Cancer Treat Res. 1996;82:359-74
pubmed: 8849962
Gynecol Oncol. 2017 Jul;146(1):94-100
pubmed: 28411948
Cancer Manag Res. 2020 Dec 14;12:12823-12840
pubmed: 33364831
BMJ. 2018 Sep 20;362:k4001
pubmed: 30237202
Perspect Psychol Sci. 2015 May;10(3):328-45
pubmed: 25987511
JAMA Surg. 2019 Jan 1;154(1):3-4
pubmed: 30326000
Comput Biol Med. 2011 Aug;41(8):575-86
pubmed: 21703607
Eur J Surg Oncol. 2006 Dec;32(10):1135-8
pubmed: 16914285
Cancer Treat Rev. 2016 Jan;42:56-72
pubmed: 26643552